Hans-Georg Pott's research while affiliated with Heinrich-Heine-Universität Düsseldorf and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (4)
Zusammenfassung
Bildgebende Verfahren nehmen heute bei der Diagnosestellung und Therapiekontrolle der Rheumatoiden Arthritis (RA) eine unverzichtbare Rolle ein. Die Initiative REMISSIONPLUS hat seit 2006 über 10 Jahre das Ziel verfolgt, moderne bildgebende Verfahren wie die Arthrosonografie und die Magnetresonanztomografie (MRT) in den klinischen A...
The German Society of Rheumatology approved new German guidelines for the sequential medical treatment of rheumatoid arthritis (RA) based on the European League Against Rheumatism (EULAR) recommendations for the management of RA published in 2010. An update of the EULAR systematic literature research was performed in Medline, Embase, and Cochrane d...
Following the EULAR recommendations published in 2010 German guidelines for the medical treatment of rheumatoid arthritis were developed based on an update of the systematic literature search and expert consensus. Methotrexate is the standard treatment option at the time of diagnosis, preferably in combination with low dose glucocorticoids. Combine...
The success of the treatment of rheumatoid arthritis depends primarily on early diagnosis. In most cases, basic therapy begins with methotrexate. Depending on the stage and course of the disease (radiographically detected early erosion and/or progression), basic immunosuppressive therapy can be combined or supplemented with cytokine antagonists. Fu...
Citations
... 10-20mg/day) along with methotrexate, tapering to the lowest possible dose, targeting doses ≤7.5mg/day within 3 months. (14) As many as 30-60% of patients with RA remain on long-term glucocorticoids. (15)(16)(17)(18) A number of patient-specific factors may lead to long-term glucocorticoid use, including refractory disease activity, worsening symptoms with glucocorticoid tapering, or inability or reluctance to take biologic therapies to control disease. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/572320989564928-1513463365036_Q64/Rieke-Alten-2.jpg)
... If remission or LDA has not been reached after 12 weeks, current treatment should be adjusted [4][5][6][7][8][9]. Patients showing some improvement in disease activity in this time period, but who have not yet achieved the treatment target, may continue with current treatment if they are expected to reach their goal by 24 weeks [10,11]. Patients with chronic diseases can experience pain, fatigue, low or depressed mood, and adverse effects of concomitant glucocorticoid use; therefore, another treatment target should be improvement in patient quality of life [3,11]. ...
... OA involves the breakdown of joint tissues in response to a number of factors, including aging, stress and trauma. The OA process can be simulated experimentally by stimulating chondrocytes with IL-1β or TNF-α, which serve prominent roles in the articular cartilage catabolism (21)(22)(23). Type II collagen is a predominant and important component of the cartilage matrix, and a decrease in type II collagen expression is one of the hallmarks of cartilage degeneration. Type II collagen occupies the vast majority of space in healthy cartilage tissue. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/278795165683720-1443481355549_Q64/Edmund-Edelmann.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272779484332034-1442047105052_Q64/Matthias-Schneider-16.jpg)
